Cargando…

Male osteoporosis

Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandeira, Leonardo, Silva, Barbara C., Bilezikian, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118818/
https://www.ncbi.nlm.nih.gov/pubmed/36382763
http://dx.doi.org/10.20945/2359-3997000000563
_version_ 1785028883082379264
author Bandeira, Leonardo
Silva, Barbara C.
Bilezikian, John P.
author_facet Bandeira, Leonardo
Silva, Barbara C.
Bilezikian, John P.
author_sort Bandeira, Leonardo
collection PubMed
description Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population. Despite these facts, only 10% of men with osteoporosis receive adequate treatment. Up to half of the cases of male osteoporosis have a secondary cause, the most common being hypogonadism, excessive alcohol consumption, and chronic use of glucocorticoids. The International Society for Clinical Densitometry (ISCD) recommends using the female database for the diagnosis of osteoporosis by DXA (T-score ≤ −2.5 in men over 50 years old). In addition, osteoporosis can also be diagnosed independently of the BMD if a fragility fracture is present, or if there is a high risk of fractures by FRAX. Treatment is similar to postmenopausal osteoporosis, because the data regarding changes in bone density track closely to those in women. Data concerning fracture risk reduction are not as certain because the clinical trials have included fewer subjects for shorter period of time. In men with symptomatic hypogonadism, testosterone replacement, if indicated, can improve BMD.
format Online
Article
Text
id pubmed-10118818
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-101188182023-04-21 Male osteoporosis Bandeira, Leonardo Silva, Barbara C. Bilezikian, John P. Arch Endocrinol Metab Review Osteoporosis, a disease classically attributed to postmenopausal women, is underappreciated, underdiagnosed, and undertreated in men. However, it is not uncommon for osteoporotic fractures to occur in men. About 40% of fractures occur in men with an incidence that has increased over the years. After a first fracture, the risk of a subsequent episode, as well as the risk of death, is higher in the male than in the female population. Despite these facts, only 10% of men with osteoporosis receive adequate treatment. Up to half of the cases of male osteoporosis have a secondary cause, the most common being hypogonadism, excessive alcohol consumption, and chronic use of glucocorticoids. The International Society for Clinical Densitometry (ISCD) recommends using the female database for the diagnosis of osteoporosis by DXA (T-score ≤ −2.5 in men over 50 years old). In addition, osteoporosis can also be diagnosed independently of the BMD if a fragility fracture is present, or if there is a high risk of fractures by FRAX. Treatment is similar to postmenopausal osteoporosis, because the data regarding changes in bone density track closely to those in women. Data concerning fracture risk reduction are not as certain because the clinical trials have included fewer subjects for shorter period of time. In men with symptomatic hypogonadism, testosterone replacement, if indicated, can improve BMD. Sociedade Brasileira de Endocrinologia e Metabologia 2022-11-11 /pmc/articles/PMC10118818/ /pubmed/36382763 http://dx.doi.org/10.20945/2359-3997000000563 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Bandeira, Leonardo
Silva, Barbara C.
Bilezikian, John P.
Male osteoporosis
title Male osteoporosis
title_full Male osteoporosis
title_fullStr Male osteoporosis
title_full_unstemmed Male osteoporosis
title_short Male osteoporosis
title_sort male osteoporosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118818/
https://www.ncbi.nlm.nih.gov/pubmed/36382763
http://dx.doi.org/10.20945/2359-3997000000563
work_keys_str_mv AT bandeiraleonardo maleosteoporosis
AT silvabarbarac maleosteoporosis
AT bilezikianjohnp maleosteoporosis